Kornimate/medical-research-clean huggingface dataset:
polarized reflectance spectroscopy for oral lesions

Conditions: Oral Cancer

Summary: in this study the investigators are conducting research to determine whether a new optical device using polarization reflectance spectroscopy can help doctors or dentists identify abnormalities in the mouth that require follow-up. to establish this, measurements are needed from a large number of individuals with different abnormalities in their mouth. the investigators believe the proposed approach has potential to improve and enable mass screening for precancerous and early cancers of the oral cavity by improving the predictive value of oral cavity exams, particularly for less experienced practitioners. the information from this study will be compared to results from the pathology report of the tissue taken from your mouth. hypothesis: 1. polarized reflectance spectroscopy can distinguish high-risk oral lesion from normal and reactive oral lesions. 2. polarized reflectance spectroscopy can capture low-grade oral lesions that have characteristics associated with a high risk of progression to cancer.

the clinician will place a fiber-optic probe designed to measure the polarized reflectance spectra over the visible optical region on a site of interest in the subject's mouth, including lesional mucosa, normal adjacent and contralateral mucosa. the site for placement of the probe will be determined by the examiner, an experienced oral pathologist. the probe examination will take no more than 15 minutes in addition to the subject's appointment time for their routine visits. a 4um unstained tissue section from surgery or biopsy, part of their scheduled care, will be requested for quantitative histological analysis. the morphometric parameters obtained from polarized reflectance measurements will be compared with the histology and quantitative pathology (nuclear phenotype score) from the tissue sections from the lesion. the collected spectra data from normal looking areas from adjacent normal looking mucosa and contralateral mucosa will be used to determine patient to patient variation in the polarized reflectance of oral mucosa.

Eligibility criteria:
inclusion criteria: * you attend the dental department at the british columbia cancer agency * you have an abnormal lesion in the mouth * you fully understand the study and give your informed consent to participate as demonstrated by signing this consent form exclusion criteria: * you are under the age of 18 years.

Keywords: mouth neoplasms mouth diseases
airway management with simulated microgravity using a submerged model

Conditions: Airway Management; Emergency Medicine

Summary: trained anesthesiologist- or emergency physician-divers will perform an airway management in simulated microgravity on a submerged model.

trained anesthesiologist- or emergency physician-divers participate in the study. simulated microgravity during spaceflight is obtained by using a submerged model. full-torso manikins is going to be used for performing airway management. each diver attempted airway management with each device (laryngeal mask, laryngeal tube, orotracheal intubation with video-assisted laryngoscope. the time for airway protection will be measured as well as the success rate.

Eligibility criteria:
inclusion criteria: * anaesthesiologist with diver licence or emergency physician with diver license exclusion criteria: * all other
the pelvic floor function and sexual life of the women after different type of hysterectomy

Conditions: Quality of Life; Urinary Incontinence; Pelvic Organ Prolapse

Summary: in this prospective, comparative non-randomized multiple teaching hospitals study, the investigators try to determine the relationship of total hysterectomy and taiwanese female pelvic floor and sexual function from the view of epidemiology and clinical survey. this is an important issue that related to female autonomy, health care resources and even national health policy. the study results will help to understand whether there is unnecessary part in the current hysterectomy procedures and its potential health hazard.

women with benign gynecology disease and indicated for laparoscopic hysterectomy (laparoscopic subtotal hysterectomy: lsh, laparoscopic cervical ligament sparing hysterectomy: clsh, laparoscopic assisted vaginal hysterectomy: lavh) are invited and explained the details of the protocol by the surgeon. the types of hysterectomy are determined by the patient and the surgeon together after discussion. all participant have to sign the informed consent. the participant will be followed up for two years after surgery. preoperative evaluation on uterine condition, pelvic floor, questionaires were recorded. the perioperative parameters including surgical time, blood loss, and postoperative parameters such as pain score, hospitalization etc were recorded. the postoperative evaluation on pelvic floor condition, questionaires etc were also recorded at different time points.

Eligibility criteria:
inclusion criteria: 1. patient who is indicated for hysterectomy due to benign gynecology disease. the participant's husband is also welcomed to join the survey of the sexual life questionnaire but this is not a necessary inclusion criteria. exclusion criteria: 1. suspect of or diagnosed as cancer patient 2. age \ 50 years old 3. menopausal woman or woman who is nulliparous 4. patient with advanced pelvic floor prolapse (stage 2, 3, 4) including uterine prolapse, cystocele, enterocele, rectocele. 5. patient with prominent urinary incontinence that affect social activity or suggested to have surgery by gynecologist or urologist. 6. patient with severe medical diseases such as liver cirrhosis, heart failure, poor control diabetes mellitus etc. 7. patient with severe pelvic inflammatory disease/tubo-ovarian abcess or pelvic endometriosis or history of severe pelvic adhesions. 8. psychiatric patients 9. patient with chronic lung disease such as bronchial asthma, bronchiectasis, chronic obstructive pulmonary disease and interstitial lung disease

Keywords: quality of life urinary incontinence pop
a single center study to evaluate the safety of the novacross microcatheter in crossing chronic total occlusions

Conditions: Chronic Total Occlusion

Summary: this is an open label, single-center, prospective, pivotal study in which the investigational device, novacross™ micro-catheter, will be tested in up to 15 patients scheduled to undergo cto-pci using an anterograde approach.


Eligibility criteria:
inclusion criteria: * adult aged 25-80 * patient understands and has signed the study informed consent form. * patient is a suitable candidate for non-emergent, coronary angioplasty * patient has an angiographic documented chronic total occlusion (i.e. \>3 months occlusion duration either by documentation or pi assessment investigator) showing distal timi flow 0. * coronary angiography of cto lesion reveals satisfactory distal vessel visualization * cto lesion is located in a coronary vessel with a reference diameter of at least 2 millimeters. * cto lesion is suitable for antegrade approach. * left ventricle ejection fraction \> 25% * body mass index (bmi) \< 40 exclusion criteria: * patient unable to give informed consent. * patient is participating in another study with any investigational drug or device. * patient is known or suspected not to tolerate the contrast agent. * aorto-ostial cto location (ostial bifurcation origins may be considered), svg cto. * intolerance to aspirin and/or inability to tolerate a second antiplatelet agent (clopidogrel and prasugrel and ticagrelor). * appearance of a fresh thrombus or intraluminal filling defects. * recent major cerebrovascular event (stroke or tia within 30 days) * significant anemia (hemoglobin \< 8.0 mg / dl) * unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty (ptca) or coronary artery bypass graft (cabg) * recent myocardial infarction (mi) (within the past two weeks) * unwillingness or inability to comply with any protocol requirements * pregnancy or nursing
autologous stromal vascular fraction in treatment of male androgenic alopecia

Conditions: Androgenic Alopecia

Summary: evaluation of safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia

40 patients with androgenic alopecia will be randomly divided into 2 groups group a (20): will receive 2 session of stromal vascular fraction directly after fat harvesting and processing and stromal vascular fraction extraction with 1 month interval . group b(20): will be injected with 2 session of platelet rich plasma 3weeks interval at site of fat harvesting and will be followed 1 month later with fat aspiration from site where platelet rich plasma was previously injected and this fat will undergo fat processing and stromal vascular fraction extraction followed by 2 session of stromal vascular fraction injection at scalp 1month interval . patients at both groups will receive topical and systemic antibiotics after stromal vascular fraction injection .

Eligibility criteria:
inclusion criteria: * male patients with androgenic alopecia exclusion criteria: * patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania. any other cutaneous disease as patients suffering from dermatological condition or a significant scarring in the treatment area. any systemic disease as autoimmune disorders , cardiac hepatic and renal patients. patients who received minoxidil or any other oral, topical medications (including herbal medications) or injection procedures for the treatment of hair loss within 6 months prior to the study, or finasteride or dutasteride within 12 months of the study

Keywords: autologous stromal vascular fraction platelet rich plasma male androgenic alopecia
study of (telintra®) in non-del(5q) myelodysplastic syndrome

Conditions: Myelodysplastic Syndrome (MDS)

Summary: this is a multicenter, single arm open label phase 2b study of oral ezatiostat (telintra®) in patients who are rbc tranfusion dependent, low to int-1 ipss risk, non-del (5q) myelodysplastic syndrome (mds).


Eligibility criteria:
inclusion criteria: * primary or de novo mds * low to intermediate-1 ipss risk of mds * ecog performance score of 0 or 1 * documentation of significant anemia with or without additional cytopenia * adequate kidney and liver function * patients must have discontinued hematopoietic growth factors at least 3 weeks prior to study entry exclusion criteria: * deletion of the 5q chromosome \[del(5q) mds\] * prior allogenic bone marrow transplant for mds * known sensitivity to ezatiostat (injection or oral tablets) * prior treatment with hypomethylating agent (hma) (e.g., azacitadine, decitabine) * history of mds ipss risk score of greater than 1.0 * pregnant or lactating women * any severe concurrent disease, infection or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry * oral steroids greater than 10 mg per day. exceptions: those prescribed for other conditions (such as new adrenal failure, asthma, arthritis) or brief sterioid use (such as tapered dosing for an acute non-mds condition) * history of hepatitis b or c, or hiv

Keywords: hematology mds myelodysplastic syndrome low risk mds int-1 risk mds transfusion dependence telintra ezatiostat ezatiostat hydrochloride tlk199 glutathione glutathione analog glutathione transferase glutathione transferase p1-1 inhibitor gst p1-1 inhibitor apoptosis differentiation enzyme inhibitor non-del (5q) non-deletion 5q
early goal directed therapy for acute kidney injury

Conditions: Kidney Injury, Acute

Summary: early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury


Eligibility criteria:
inclusion criteria: * over 18 years old * occurence of the early phase of acute kidney injury * stay on intensive care unit exclusion criteria: * chronic haemodialysis * not given informed consent
light therapy for chemotherapy induced peripheral neuropathy in childhood cancer survivors

Conditions: Cancer; Childhood Cancer; Chemotherapy-induced Peripheral Neuropathy

Summary: the purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of chemotherapy induced peripheral neuropathy (cipn) at baseline and following completion of the at-home light therapy protocol.

this prospective single-arm pilot study will assess the feasibility of a 6-week at-home light therapy intervention for cipn. survivors of childhood cancer (\<21 years at diagnosis), ages five years or older at the time of survivorship clinic visit, with a history of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause cipn, will be included if they have cipn (defined as a score of four or higher on the pediatric modified total neuropathy score for survivors \<18 years old at evaluation, or the modified total neuropathy score for survivors 18 years or older at evaluation). the primary outcome of the study will be feasibility of the at-home protocol, measured as proportion of survivors who complete at least 12 at-home light therapy sessions, with ≥70% of survivors completing 12 or more sessions indicating feasibility. secondary outcomes include 1) proportion of survivors satisfied with intervention, measured as a mean score of 3 or higher on a 4-point likert-scale survey 2) facilitators and barriers to implementation of light-therapy, assessed by semi-structured qualitative interviews with 5-10 survivors who adhered and did not adhere to the protocol, and 3) change in neuropathy symptoms (measured by change in modified total neuropathy score or pediatric-modified total neuropathy score, and gait speed) from baseline to 1 week post intervention.

Eligibility criteria:
inclusion criteria: * history of childhood cancer (\<21 years of age at diagnosis) * current age five years or older (due to availability of validated measures for cipn in this age group) * history of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause cipn * cipn as assessed by a trained physical therapist defined as a score of four or higher on the ped-mtns (for survivors \<18 years old at evaluation), or the mtns (for survivors 18 years or older at evaluation) exclusion criteria: * currently pregnant or lactating (by patient report, at initiation or at any point of the study) * inability to sit still for at least 15 minutes * diagnosis of neuropathy prior to cancer treatment * active cancer diagnosis or cancerous skin lesion * central nervous system tumor (due to lack of validated measures for cipn in this population) * cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.

Keywords: survivors of childhood cancer
4d-310 in adults with fabry disease and cardiac involvement

Conditions: Fabry Disease

Summary: this is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4d-310 following a single iv administration. the study population is comprised of adult males and females with fabry disease and cardiac involvement

this is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4d-310 following a single iv administration. the study population is comprised of adult males and females with fabry disease and cardiac involvement

Eligibility criteria:
inclusion criteria: 1. male or female ≥ 18 to ≤65 years of age 2. pathogenic gla mutation consistent with fabry disease 3. confirmed diagnosis of classic or late-onset fabry disease with cardiac involvement 4. intolerant of ert, unable or unwilling to receive ert, or progressive disease despite ert or migalastat 5. individuals receiving ert, must be on a stable dose for at least 6 months 6. agree to use highly effective contraception exclusion criteria: 1. presence of pre-existing antibodies to 4d-310 capsid or to aga 2. egfr \<65 ml/min/1.73 m2 3. undergone kidney transplantation or currently on hemodialysis or peritoneal dialysis 4. hiv, active or chronic hepatitis b or c, 5. evidence of liver disease, severe pulmonary disease or diabetes with poor glycemic control 6. history of stroke or transient ischemic attack within the last 12 months, or other significant thromboembolic disease history (e.g. pulmonary embolism) 7. contraindication to systemic corticosteroid therapy or immunosuppressive therapy 8. chronic steroid use, defined as ≥ 3 months of oral corticosteroid use within the last 12 months. 9. moderately severe to severe cardiovascular disease or uncontrolled hypertension 10. left ventricular ejection fraction of \<45% on echocardiogram (echo) 11. currently receiving investigational drug, device or therapy or having ever received gene therapy 12. history of infusion related response to ert or any adverse reaction leading to ert discontinuation 13. history of cancer within 2 years (exceptions include non-melanoma skin cancer, localized prostate cancer treated with curative intent) 14. pregnant or breast-feeding note: other inclusion and exclusion criteria apply

Keywords: lysosomal storage diseases nervous system brain diseases metabolic inborn brain diseases central nervous system diseases nervous system diseases cerebral small vessel diseases cerebrovascular disorders vascular diseases cardiovascular diseases genetic diseases x-linked inborn metabolic diseases lipid metabolism disorders sphingolipidoses metabolism inborn errors lipidoses lipid metabolism
hepatic function and bile acid in preterm infants receiving parenteral lipids emulsion

Conditions: Preterm Infants

Summary: the etiology of parenteral nutrition-associated cholestasis(pnac)although elusive is thought to be multifactorial, and proposed theories also include problems arising from lipid emulsions, leading us to explore alternative products available elsewhere.so we compare the different fat emulsion, and want to see if the olive oil lipid emulsions can improve hepatic tolerance in preterm infant.

parenteral nutrition (pn) has been widely and successfully used in the pediatric population for more than 40 years, the most serious and significant life-threatening complication today continues to be parenteral nutrition-associated cholestasis(pnac). parenteral nutrition-associated cholestasis is indeed the most worrisome complication because it is difficult to treat and may progress to eventual cirrhosis and liver failure namely parenteral nutrition-associated liver disease (pnald). two types of lipid emulsions are currently used for adult as well as pediatric patients: one lipid emulsions prepared from soybean oil that are composed of long-chain triacylglycerols (lcts), and the other lipid emulsions composed of 50% medium-chain triacylglycerols (mcts) and 50% lct soybean oil. a new lipid emulsion prepared from a mixture of soybean oil and olive oil contains only lcts and has a lower proportion (20%) of polyunsaturated fatty acids(pufas)and 60% monounsaturated fatty acids (mufas). so we compare the different fat emulsion, and want to see if the olive oil lipid emulsions can improve hepatic tolerance in preterm infant.

Eligibility criteria:
inclusion criteria: * infants of both genders * hospitalized * the parent of the infant agreed to participate by signing an informed consent form * infants admitted hospital within 72 hours after birth(gestational age\<37 weeks) * birth weight \<= 2000g * no pn support contraindications * parenteral nutrition for 14 days or more * the parent of the infant is to sign an informed consent form prior to enrollment exclusion criteria: * receiving pn before screening * enteral nutrition(en)caloric\>10% * obstruction jaundice * suspected or identified biliary tract atresia * neonatal hepatitis * infants with liver markers \>2 times normal levels * infants with renal markers \>2 times normal levels * congenital metabolic situations * identified as having major chromosomal disease * cytomegaoviyns(cmv), virus hepatitis and syphilis infection * congenital or acquired immune deficiency

Keywords: lipids preterm infants parenteral nutrition liver function
effects of nursing staff on empiric antibiotic in septic shock

Conditions: Septic Shock; Compliance; Antibiotic; Nursing Caries

Summary: a retrospective, observational study was performed about the patients with septic shock who admitted into intensive care unit (icu) from january 1, 2015 to february 29, 2016. the number of patients who received empiric antibiotic treatment within first hour after septic shock diagnosis were collected. detailed information about clinical ladder for nursing stuff and nursing shift were collected . clinical ladder for nursing stuff is a new definition based on education background and work experience and nurses stuff are classified into four levels. n0 was defined who got college degree or above, nurse qualification certificate and working time less than one year. n1 an n2 were defined as who got nurse qualification certificate and working time between 1\~3 years and more than three years, respectively. n3 was defined who was nurse-in-charge qualification or got nurse practitioner qualification for more than five years. compliance of empiric antibiotic treatment within first hour and evaluate the effect of nursing stuff on the compliance were calculated.


Eligibility criteria:
inclusion criteria: * age\>18 years old * sepsis exclusion criteria: * pregnancy * \>80 years old.
midodrine for the treatment of refractory hypotension

Conditions: Hypotension; Critical Illness

Summary: we hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready for discharge from the icu shortens duration of receiving iv vasopressors and sicu length of stay without increasing mgh length of stay or putting the patient at risk of being readmitted to an icu.

persistent hypotension in critically ill patients remains a major barrier to discharging patients from the intensive care unit (icu). in our hospital, in patients with adequate tissue perfusion, midodrine has been observed to treat hypotension in order to wean continuous intravenous (iv) vasopressors and therefore promote icu discharge. there are several possible etiologies of hypotension in the icu. the most frequently seen causes include septic shock, hypovolemia, adrenal insufficiency, and idiosyncratic reactions from medications. for patients whose reversible causes of hypotension have been addressed but still require vasopressors, midodrine may prove to be a useful adjunctive medication to successfully increase blood pressure. no previous studies have examined the use of midodrine for the treatment of hypotension in an icu setting. therefore, we are investigating a new indication for midodrine as the treatment of hypotension in critically ill patients.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * admitted to the sicu * requiring iv vasopressors at a rate of less than 100 mcg/min of phenylephrine, or 8 mcg/min of norepinephrine, or 60 mcg/min of metaraminol; and unable to wean for more than 24 hours while still maintaining desired blood pressure goal exclusion criteria: * inadequate tissue oxygenation * liver failure * renal failure * hypovolemic shock or hypotension due to adrenal insufficiency * pregnancy * severe organic heart disease * urinary retention * pheochromocytoma * thyrotoxicosis * midodrine as pre-admission medication * any known allergies to midodrine * enrollment in another clinical trial

Keywords: midodrine hypotension intensive care unit iv vasopressors icu discharge